Advances in pediatric rhabdomyosarcoma characterization and disease model development
- PMID: 22127592
- PMCID: PMC3922709
- DOI: 10.14670/HH-27.13
Advances in pediatric rhabdomyosarcoma characterization and disease model development
Abstract
Rhabdomyosarcoma (RMS), a form of soft tissue sarcoma, is one of the most common pediatric malignancies. A complex disease with at least three different subtypes, it is characterized by perturbations in a number of signaling pathways and genetic abnormalities. Extensive clinical studies have helped classify these tumors into high and low risk groups to facilitate different treatment regimens. Research into the etiology of the disease has helped uncover numerous potential therapeutic intervention points which can be tested on various animal models of RMS; both genetically modified models and tumor xenograft models. Taken together, there has been a marked increase in the survival rate of RMS patients but the highly invasive, metastatic forms of the disease continue to baffle researchers. This review aims to highlight and summarize some of the most important developments in characterization and in vivo model generation for RMS research, in the last few decades.
Figures
Similar articles
-
Cytogenetic studies in subgroups of rhabdomyosarcoma.Genes Chromosomes Cancer. 1992 Nov;5(4):299-310. doi: 10.1002/gcc.2870050405. Genes Chromosomes Cancer. 1992. PMID: 1283318
-
Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.Genes (Basel). 2021 Sep 25;12(10):1500. doi: 10.3390/genes12101500. Genes (Basel). 2021. PMID: 34680895 Free PMC article. Review.
-
Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma.Urol Oncol. 2016 Feb;34(2):103-15. doi: 10.1016/j.urolonc.2015.09.013. Epub 2015 Oct 28. Urol Oncol. 2016. PMID: 26519985 Review.
-
Zebrafish Rhabdomyosarcoma.Adv Exp Med Biol. 2016;916:371-89. doi: 10.1007/978-3-319-30654-4_16. Adv Exp Med Biol. 2016. PMID: 27165362 Review.
-
DNA repair systems in rhabdomyosarcoma.Histol Histopathol. 2013 Aug;28(8):971-84. doi: 10.14670/HH-28.971. Epub 2013 Mar 21. Histol Histopathol. 2013. PMID: 23516236 Review.
Cited by
-
Fenretinide Acts as Potent Radiosensitizer for Treatment of Rhabdomyosarcoma Cells.Front Oncol. 2021 Jun 15;11:664462. doi: 10.3389/fonc.2021.664462. eCollection 2021. Front Oncol. 2021. PMID: 34211841 Free PMC article.
-
Targeting PI3K/Akt represses Hypoxia inducible factor-1α activation and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for apoptosis.Cancer Cell Int. 2013 Apr 16;13:36. doi: 10.1186/1475-2867-13-36. eCollection 2013. Cancer Cell Int. 2013. PMID: 23590596 Free PMC article.
-
Germline predisposition to genitourinary rhabdomyosarcoma.Transl Androl Urol. 2020 Oct;9(5):2430-2440. doi: 10.21037/tau-20-76. Transl Androl Urol. 2020. PMID: 33209717 Free PMC article. Review.
-
DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.Oncotarget. 2016 Nov 29;7(48):79342-79356. doi: 10.18632/oncotarget.12688. Oncotarget. 2016. PMID: 27764816 Free PMC article.
-
Synthetic inhibition of the SUMO pathway by targeting the SAE1 component via TAK-981 compound impairs growth and chemosensitizes embryonal and alveolar rhabdomyosarcoma cell lines.Mol Cell Biochem. 2025 Jun 23. doi: 10.1007/s11010-025-05336-6. Online ahead of print. Mol Cell Biochem. 2025. PMID: 40549307
References
-
- Bartel F, Taylor AC, Taubert H, Harris LC. Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol. Res. 2001a;12:451–457. - PubMed
-
- Bartel F, Meye A, Wurl P, Kappler M, Bache M, Lautenschlager C, Grunbaum U, Schmidt H, Taubert H. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer. 2001b;95:168–175. - PubMed
-
- Bartel F, Schulz J, Bohnke A, Blumke K, Kappler M, Bache M, Schmidt H, Wurl P, Taubert H, Hauptmann S. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int. J. Cancer. 2005;117:469–475. - PubMed
-
- Bennicelli JL, Fredericks WJ, Wilson RB, Rauscher FJ, 3rd, Barr FG. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene. 1995;11:119–130. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources